Chemed Corporation reported financial results for the third quarter ended September 30, 2026, via an 8-K filing. The company, which operates VITAS Healthcare and Roto-Rooter, reported consolidated revenue of $690.9 million for the quarter, representing a 10.6% increase compared to the prior year.
Consolidated GAAP diluted earnings per share (EPS) were $5.45, an increase of 22.2% year-over-year. Adjusted diluted EPS was $6.75, up 28.1%.
The VITAS Healthcare segment saw significant growth. Net patient revenue rose 12.2% to $457.4 million. This was driven by a 9.4% increase in days-of-care and a 2.2% increase in Medicare reimbursement rates. The segment reported net income of $70.8 million, up 44.7%.
In contrast, the Roto-Rooter segment generated $233.5 million in revenue, a 7.5% increase. However, the segment reported a decline in adjusted EBITDA to $48.2 million, down 2.5%. Roto-Rooter also incurred higher selling, general, and administrative expenses, which increased 17.1% to $71.0 million.
Chemed announced that it repurchased 125,000 shares of its stock during the quarter for approximately $66.0 million. The company also re-acquired multiple franchise territories in California for about $62.5 million. As of September 30, 2026, Chemed had $48.4 million in cash and $236.0 million in long-term debt.
Management stated that results through September 30, 2026, suggest the company will be at or slightly above the high-end of its full-year 2026 adjusted EPS guidance. The company will host a conference call on October 28, 2026, to discuss these results in further detail.
